Meerjarige wortelonkruiden : onderzoeksplan

Er zijn op akkerbouwbedrijven, vooral op biologisch, problemen met de bestrijding van meerjarige wortelonkruiden. Het probleem wordt ook steeds groter. Door middel van biologische grond ontsmetting (BGO) wordt het aantal meerjarige wortelonkruiden verminderd, maar hoeveel en hoe sterk dat is, is niet bekend. Het effect van BGO werd voornamelijk onderzocht op het onkruid akkermelkdistel. Dit onderzoek werd uitgevoerd door PPO-AGV te Lelystad geholpen door leerlingen van de CAH Dronten. Het onderzoek is een echte proef van PPO en geeft studenten de kans om te leren hoe het in de praktijk gaat met uitvoering en verwerking van gegevens in het onderzoek

Lespakket groenbemesters

Lesmateriaal dat opgenomen is in het Groen Kennisnet dossier Groenbemesters (WURKS-project). Er zijn casussen (verwerkingsopdrachten) gemaakt over bodemkwaliteit voor diverse grondsoorten (klei, zand) en sectoren (akkerbouw, melkveehouderij, gemengd) die voor zowel MBO- als HBO geschikt zijn. De casussen zijn als zodanig te gebruiken, maar kunnen ook ideeën geven voor het maken van eigen opdrachten

Toepassingsmogelijkheden van ziektewering in de praktijk

In dit artikel gaat het over ziektewering voornamelijk als gevolg van biologische oorzaken. Dit is het gehele complex van bodemflora en -fauna die interacteren met het pathogeen, de omgeving en met het gewas. Er is een algemene ziektwering en een specifieke ziektewering te onderscheiden. Besproken worden de intensief onderzochte pathogeen-gewas combinaties tarwehalmdoder - tarwe en Rhizoctonia solani - bloemkool/suikerbiet/aardappel. Verder het maximaliseren van de bodemweerbaarheid en het tegengaan van verlaging van de bodemweerbaarheid

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose

Contains fulltext : 218191.pdf (Publisher’s version ) (Open Access)Tyrosine kinase inhibitors (TKIs) are anti-cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in a fixed dose, although large interpatient pharmacokinetic (PK) variability is described. For imatinib, sunitinib and pazopanib exposure-treatment outcome (efficacy and toxicity) relationships have been established and therapeutic windows have been defined, therefore dose optimization based on the measured blood concentration, called therapeutic drug monitoring (TDM), can be valuable in increasing efficacy and reducing the toxicity of these drugs. In this review, an overview of the current knowledge on TDM guided individualized dosing of imatinib, sunitinib and pazopanib for the treatment of solid tumours is presented. We summarize preclinical and clinical data that have defined thresholds for efficacy and toxicity. Furthermore, PK models and factors that influence the PK of these drugs which partly explain the interpatient PK variability are summarized. Finally, pharmacological interventions that have been performed to optimize plasma concentrations are described. Based on current literature, we advise which methods should be used to optimize exposure to imatinib, sunitinib and pazopanib

The value of the neutrophil-lymphocyte count ratio in the diagnosis of sepsis in patients admitted to the Intensive Care Unit: A retrospective cohort study

Contains fulltext : 202166.pdf (publisher's version ) (Open Access

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients

PurposePazopanib is known to cause liver toxicity. A relationship between pazopanib exposure and alanine transaminase elevations has been described in clinical trials. This study investigated the relation between pazopanib exposure and liver toxicity in real-world patients and evaluated the management of pazopanib-induced liver toxicity in routine care.MethodsA retrospective observational cohort study was performed in patients treated with pazopanib in whom pazopanib exposure was measured. The percentage of patients with and without liver toxicity during treatment with pazopanib was calculated as well as the average pazopanib exposure in both groups. Furthermore, the management of patients with liver toxicity was evaluated.ResultsLiver toxicity was observed in 25 out of the 133 patients included (19%). Pazopanib exposure was comparable in patients with or without liver toxicity (27.7 mg/L versus 28.1 mg/L). Seven patients permanently discontinued pazopanib after the occurrence of liver toxicity. Of the remaining 18 patients, continuation or restart of pazopanib after liver toxicity was successful in 16 patients and half of these patients were able to safely continue pazopanib at the same dose as prior to liver toxicity for the remaining duration of treatment.ConclusionOur study did not demonstrate a clear relationship between pazopanib exposure and the occurrence of pazopanib-induced liver toxicity. Half of the patients were able to safely continue or restart pazopanib treatment after liver toxicity and received the same dose as prior to drug withdrawal. Successful interventions to address pazopanib-induced toxicity in the clinic led to an algorithm for the management of pazopanib-induced liver toxicity